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RESPONSE
Andrew Moore and colleagues reply to Des Spence
Andrew Moore honorary senior research fellow 1, Phil Wiffen honorary professor 1, Christopher
Eccleston professor 2, Michael Lunn consultant neurologist 3, Richard Hughes honorary professor 3,
Amanda Williams clinical reader 4, Dominic Aldington consultant anaesthetist, consultant in pain
management 5, Eija Kalso professor 6
1Pain Research and Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 7LE, UK;
2Centre for Pain Research, University of Bath, Bath, UK; 3National Hospital for Neurology and Neurosurgery and MRC Centre for Neuromuscular
Diseases, London, UK; 4Research Department of Clinical, Educational, and Health Psychology, University College London, London, UK; 5Royal
Hampshire County Hospital, Winchester, UK; 6Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki and Pain Clinic, Department
of Anaesthesia and Intensive Care Medicine, Helsinki University Central Hospital, Helsinki, Finland
Spence’s polemic on duloxetine loses power because most of
what it is based on is wrong.1 Making pronouncements in
respected journals about good and bad medicine comes with
the responsibility of knowing what you are talking about. Bad
scholarship helps no one, especially those in pain; research in
genetics, neurobiology, and psychology has contributed to huge
advances in knowledge about the bio-psycho-social origins of
pain.
Chronic pain is defined as pain of moderate or severe intensity
that lasts for three months or more (think of a really bad
headache lasting from Christmas to Easter). It affects one in
five adults. Painful conditions are among the most prevalent
conditions and are five of the top 11 in terms of years living
with disability. Chronic pain destroys lives, has a huge negative
impact on quality of life, is costly, reduces the ability to work
or function inside the family, and may be associated with
decreased life expectancy.
Here is a brief, non-comprehensive list of where Spence misses
the point.
Women are not over-represented in trials. Chronic pain
disproportionately affects women; their representation matches
the epidemiology.
Pain is the most immediate of patient outcome measures,
reported by patients themselves. Its subjectivity was recognised
in the 1950s and dealt with. Different scales show excellent
agreement, and patients in clinical trials record consistent pain
levels over long periods, as in clinical practice.
Average benefits over placebo are in the order of 1 point on a
10 point rating score. But few patients are average; most have
either little or great benefit. A responder is defined as someone
with at least a 50% reduction in pain intensity maintained for
12 weeks, without intolerable adverse events that mean stopping
treatment. Patients want this outcome, and it is accompanied
by major improvements in sleep, function, and quality of life.
Cochrane reviews do not report effective non-drug alternatives.
One of exercise in fibromyalgia involved only 223 patients in
four small trials of barely adequate quality; another of
psychological therapies found that effects are at best weak and
that more research is urgently needed.2
Cochrane reviews endorse nothing.3 Several large good quality
trials provide good evidence that duloxetine is effective in
painful diabetic neuropathy and fibromyalgia. The effect size
is not massive—a number needed to treat of five tells you
that—but it is comparable to other treatments in neuropathic
and other chronic pain, where treatment failure is expected more
often than treatment success.4
We are not “steeped in conflicts of interest.” Some (but not all)
make declarations of interest, not quite the same as conflicts.
We are proud of this, when it means bringing otherwise
unpublished information into the public domain, accessing data
at the level of the individual patient to improve understanding
of evidence and outcomes, and, importantly, demonstrating new
sources of large potential bias. Our rule over 30 years is that we
work only with organisations that agree an unrestricted right to
publish the results, whatever they may be.
Spence omits the most important, valid, criticisms. These might
include the bias against older treatments because authorities
require trials fundable only by industry or government (which
neither fund). Effective drugs like amitriptyline are understudied
so have less evidence of efficacy to support their use. In
addition, inappropriate imputationmethods in statistical analysis
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of results can mean that efficacy is sometimes hugely inflated5;
this is not the case for duloxetine.6
Patients need options. Encouraging people to act against the
evidence is the real “bad medicine.”
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